Is CavilonTM Durable Barrier Cream (treatment) more effective than 100% Pure Sorbolene Cream (control) at preventing moist desquamation in patients receiving radiation treatment to the breast in a tropical setting?

Townsville Health Service District0 个研究点目标入组 300 人开始时间: 2012年7月24日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Patients undergoing radiation treatment at the Radiation Oncology Unit, The Townsville Hospital, for cancer of the breast, and who:
•1. Are 18 years or older, and
•2. Are able to read, write, and speak English and able to comprehend and follow the study instructions, and
•3. Are willing to consent to their inclusion in the study.

•Patients undergoing radiation treatment at the Radiation Oncology Unit, The Townsville Hospital, for cancer of the breast, and who:
•1. Are undergoing radiation therapy for palliative reasons, and/or
•2. Have specific breast lesions that receive treatment that differs significantly in terms of dosage and duration to the routine regimen, and/or
•3. Have a known allergy to either Sorbolene or Cavilon cream, and/or
•4. Are unable to provide their written consent owing to an intellectual or mental impairment, and/or
•5. Are deemed by the Radiation Oncologist to be not suitable to be invited to participate in the study, and/or
•6. Decline to participate.

发起方

Townsville Health Service District